Johnson Controls (JCI)
NYSEIndustrialsConstruction MaterialsSnapshot 2026-09-14
$138.29+0.38%
Close 2026-09-15 · 1-day change
NYSEIndustrialsConstruction MaterialsSnapshot 2026-09-14
Research Workspace
Put JCI beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Building Products is in recovery. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Recent financial performance freshly dropped to the bottom half of its industry.
View ThesisRevenue is growing steadily — about 7% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens strong on capital allocation, earnings delivery, market reaction to earnings.
View ManagementExpectations look high — the market is pricing in about 38% growth a year, above the roughly 10% analysts expect, leaving little room for error.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskJCI's growth has to keep compounding to justify the price. Revenue grew 9% year over year, and the last quarter beat expectations. JCI trades at 31× P/E versus a peer median of 18×. The market is pricing in more growth than we forecast. Recent financial performance dropped to the bottom half of its industry. Our model puts the next-quarter miss near 19%. Peer multiples imply a price about 46% below where it trades. The thesis has broken.
Trailing returns as of 2026-09-15. JCI is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 21 analysts currently covering JCI (as of Sep 2026).
Based on 5 Wall Street analysts offering 12-month price targets for JCI in the last 4 months.
Continue this research
Compare JCI with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| JCI Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 13 valuation methods, at three horizons. As of 2026-09-14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Building Products — fair value, gap to price, and forward P/E.
Compare the value case
Put JCI next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Achieve organic sales growth of ~6% for fiscal 2026
Strong revenue growth supports organic sales growth objective.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-15. EPS is implied from price ÷ P/E. Not investment advice.
Current $138.29
The last 12 months of price, then the range of analyst 12-month targets from today’s $138.29.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Achieve adjusted EPS of ~$4.85 for fiscal 2026
Increased profit forecast supports EPS growth objective.
Advances: Achieve organic sales growth of ~6% for fiscal 2026
Better-than-expected sales directly support sales growth objective.
New board member may enhance strategic decision-making.
Earnings beat indicates strong operational performance.
Positive earnings outlook supports growth expectations.